Joshua Brody

Joshua Brody: Which steroid is right for CRS?

Joshua Brody, Associate Professor, Division of Hematology and Oncology at Icahn School of Medicine at Mount Sinai, shared on LinkedIn about a recent paper by Lorenzo Falchi et al.:

“Which steroid is right for CRS?
Hint: It rhymes with dexamethasone”

Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphoma

Authors: Lorenzo Falchi et al.

Joshua Brody

cancer CRS Icahn School of Medicine Joshua Brody OncoDaily Oncology